Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer - Takeaways - MDSpire

Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer

  • By

  • Wolfgang Lilleby

  • Amar Kishan

  • Hans Geinitz

  • January 20, 2024

  • 0 min

Share

  • 1

    Hypofractionated radiotherapy (Hypo-RT) is an effective treatment for localized prostate cancer, offering shorter treatment schedules.

  • 2

    Acute and long-term toxicity from Hypo-RT can significantly affect patients' quality of life and may require additional medical interventions.

  • 3

    Patient-reported outcomes (PROs) are essential for accurately assessing adverse events, as patients often report more severe symptoms than physicians.

  • 4

    Validated questionnaires like EPIC-26 and EORTC QLQ are crucial tools for measuring quality of life and treatment-related symptoms in prostate cancer patients.

  • 5

    Recent advances in radiotherapy techniques have improved the safety and efficacy of Hypo-RT, widening the therapeutic window for localized prostate cancer.

Original Source(s)

Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer

  • by Wolfgang Lilleby, Amar Kishan, Hans Geinitz

  • January 20, 2024

Related Content

Beyond Treatment Volume: When Pelvic Radiotherapy May Still Matter in High-Risk Localised Prostate Cancer

State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature

Biochemical Tumor Markers: Are New Testing Guidelines Fit for Purpose?

CLSI guidance achieves technical excellence but has some questionable omissions, says Mustafa Barbhuiya